Restoring Hormone Balance With an Integrative Approach

Abstract

In this educational post, I walk you through a comprehensive, patient-centered approach to menstrual health, iron deficiency, polycystic ovary syndrome (PCOS), post-bariatric care, and testosterone therapy. Using current research and my clinical experience, I explain how cyclic progesterone, iron replenishment, thyroid health, estrogen management, SHBG levels, and careful androgen dosing work in the body. I also describe how integrative chiropractic care fits into this continuum: modulating autonomic tone, improving microvascular perfusion, reducing inflammatory burden, and enhancing tissue-level hormone signaling, all in synergy with pharmacologic therapies. My goal is to make these concepts easy to follow while honoring their complexity, so you can apply them safely and effectively.

Introduction: My Integrative Framework for Hormone and Menstrual Health

As a clinician working at the intersection of functional medicine, primary care, and chiropractic, I see a consistent pattern: patients do best when we integrate hormonal physiology, micronutrient status, metabolic fitness, and musculoskeletal-autonomic regulation. In this post, I reword and expand on common clinical themes—from iron deficiency and cyclic progesterone to testosterone pellets and SHBG—and present them through the lens of systems physiology. I include my observations from daily practice and research curation, and explain how integrative chiropractic care enhances outcomes alongside endocrine therapies.

Key themes you will learn:

• Why iron deficiency and thyroid status shape uterine bleeding and energy
• How cyclic progesterone reduces heavy bleeding and stabilizes cycles
• The rationale for testosterone dosing is based on absorption, distribution, and renal excretion
• How SHBG impairs symptom response and how to navigate contraception in perimenopause
• What to consider in post-bariatric patients with malabsorption and microbiome shifts
• When to use nutraceuticals like DIM and when to reassess dosing rather than block estrogen
• Where integrative chiropractic care fits: autonomic balance, perfusion, pain modulation, and exercise readiness

Iron Deficiency, Thyroid Function, and Menstrual Bleeding: The Foundational Physiologic Loop

When a woman presents with heavy or prolonged bleeding, the first move is to put the right team in the room—medical, nutritional, and integrative clinicians—to assess the foundational loops. Iron deficiency and thyroid dysfunction frequently co-occur with abnormal uterine bleeding.

• Iron deficiency physiology:
  • Iron is essential for hemoglobin synthesis and oxygen transport. Low ferritin and transferrin saturation impede oxygen delivery to endometrial tissue and impair mitochondrial function, driving fatigue and amplifying bleeding-related symptoms (Pasricha et al., 2021).
  • Iron status also influences coagulation and platelet function; deficiency can contribute to dysfunctional hemostasis in the endometrium (Goddard et al., 2011).
  • Clinically, I find that women with ferritin levels below 30–50 ng/mL and transferrin saturation under 20% are more likely to have fatigue, exertional tachycardia, and heavier menses. Repleting iron normalizes energy and bleeding curves.
• Thyroid function and endometrial dynamics:
  • Hypothyroidism is linked to menorrhagia via altered estrogen metabolism, increased TRH-induced prolactin (affecting gonadotropins), and changes in coagulation factors (Krassas et al., 2010).
  • Normalizing TSH, free T4, and free T3 improves endometrial receptivity and cycle regularity.
• Practical steps:
  • Assess CBC, ferritin, iron panel, TSH, free T4/T3, and CRP.
  • Initiate oral iron (e.g., ferrous bisglycinate 25–50 mg elemental iron daily) or IV iron if malabsorption or intolerance is present, and correct thyroid abnormalities according to evidence-based protocols (Cappellini et al., 2020; Krassas et al., 2010).
  • Combine with cyclic progesterone to stabilize bleeding while the iron-thyroid axis is addressed.

Why Cyclic Progesterone Helps Heavy Bleeding

Progesterone counterbalances estrogen-driven endometrial proliferation. In luteal-phase physiology, progesterone induces secretory transformation and promotes orderly endometrial shedding.

• Mechanism:
  • Reduces endometrial angiogenesis and matrix metalloproteinase expression, thereby lowering bleeding (Maybin & Critchley, 2015).
  • Modulates myometrial contractility and prostaglandins, easing dysmenorrhea.
• Clinical use:
  • For heavy bleeding, I often start with cyclic oral micronized progesterone (e.g., 200 mg nightly days 14–28) for several cycles, then reassess flow and ferritin.
  • In higher bleeding burden, extending progesterone cycles or increasing dose (e.g., 200 mg for 10–14 days per cycle, then taper) can stabilize the endometrium while iron repletion occurs.
• Why this works:
  • It addresses the source of bleeding (endometrial stability) while iron replaces losses and thyroid normalizes systemic metabolism.

PCOS: Metabolic and Hormonal Nuances

PCOS is characterized by hyperandrogenism, ovulatory dysfunction, and insulin resistance, with elevated LH:FSH ratios in many patients. Treatment must respect cardiometabolic risk and fertility goals.

• Physiology:
  • Insulin resistance increases ovarian androgen production and decreases SHBG, raising free testosterone and exacerbating symptoms (Azziz et al., 2016).
  • Chronic low-grade inflammation and adiposity contribute to dysregulated ovulation and endometrial health.
• Interventions:
  • Lifestyle: structured exercise, sleep optimization, and low-glycemic nutrition improve insulin sensitivity and SHBG.
  • Cyclic progesterone can regulate bleeding and protect the endometrium in anovulatory cycles.
  • Metformin and incretin-based therapies can be used in appropriate patients to restore ovulation and metabolic health (Legro et al., 2013).
• My observation:
  • In PCOS, responding to bleeding with progesterone cycling while normalizing iron and thyroid often accelerates symptomatic relief. I also emphasize autonomic and musculoskeletal support through integrative chiropractic care to help patients sustain exercise and reduce stress-related cortisol surges.

Post-Gastric Bypass: Malabsorption, Microbiome, and Hormone Therapy

After bariatric procedures, patients face unique absorption challenges and shifts in the microbiome.

• Nutritional physiology:
  • Reduced gastric volume and altered small bowel transit impair absorption of iron, B12, fat-soluble vitamins, and some pharmaceuticals (Mechanick et al., 2020).
  • Microbiome changes influence estrogen metabolism via the estrobolome, affecting systemic estrogen signaling.
• Practical approach:
  • Use bioavailable forms and consider parenteral iron or B12 if deficits persist.
  • Employ targeted probiotics to improve gut barrier integrity and help restore metabolite balance (Sánchez-Tapia et al., 2020). While probiotics are not a panacea, certain strains support post-bariatric gut health.
• Hormone therapy considerations:
  • In malabsorption, transdermal or pellet delivery of hormones may bypass GI variability.
  • Monitor levels and symptoms closely—absorption can be erratic early post-op.
• My clinical stance:
  • I treat core physiology the same—correct deficiencies, stabilize bleeding with progesterone when indicated, and titrate hormone therapy with careful lab and symptom follow-up. If absorption appears unreliable, I switch route or consider parenteral repletion.

Androgen Therapy: Absorption, Distribution, and Renal Excretion

Successful testosterone therapy hinges on three pharmacokinetic pillars—absorption, distribution, and excretion.

• Absorption:
  • Subcutaneous pellets and transdermal gels rely on capillary perfusion of subcutaneous tissue. Higher cardiac output and regional blood flow enhance early release kinetics.
  • Exercise improves perfusion, often yielding faster attainment of steady-state levels.
• Distribution:
  • Testosterone distributes across the total body water and adipose compartments. Higher BMI and adiposity can dilute effective concentrations, altering clinical response despite equal dosing (Saad et al., 2017).
• Excretion:
  • Testosterone and metabolites are cleared via hepatic metabolism and renal excretion of conjugates. In older patients or those with reduced renal function, the effective half-life can be prolonged, causing lower doses to last longer (Corona et al., 2014).
• Clinical implications:
  • Patients who lose 20% of body fat often require lower maintenance dosing, as distribution volume narrows.
  • In octogenarian men, I often use lower pellet loads; kinetics stretch out, sometimes giving 6–9 months of symptom relief on modest doses.
• Why avoid reflex estrogen blockers:
  • Breast tenderness in men typically occurs during the initial rapid rise in testosterone, not in stable maintenance. If tenderness persists, first evaluate dose and timing rather than immediately adding aromatase inhibitors.
  • DIM (diindolylmethane) may support estrogen metabolism in select cases, but I prioritize dose calibration and improvements in body composition over blocking estradiol, given estradiol’s role in bone, brain, and cardiovascular health (Finkelstein et al., 2013).

SHBG, Contraception, and Female Androgen Response

Sex hormone–binding globulin (SHBG) regulates the availability of free hormones. Elevated SHBG can blunt the response to testosterone therapy in women.

• Physiology:
  • SHBG binds testosterone and estradiol; only free and albumin-bound fractions are bioactive. Combined oral contraceptives often increase SHBG, reducing free testosterone (Zimmerman et al., 2014).
• Clinical scenario:
  • A 45-year-old woman on combined contraceptives may have SHBG >100 nmol/L, rendering standard testosterone doses ineffective. Clinically, she “doesn’t feel a smidge” of benefit until total T is very high—an approach I avoid for safety reasons and because it’s unnecessary.
• Strategy:
  • If contraception is required, consider non-estrogen options:
    • Levonorgestrel IUD for local progestin effect without raising SHBG substantially
    • Copper IUD if appropriate
  • By reducing SHBG’s impact, a physiologic testosterone dose can produce meaningful symptom relief.
• Risk-benefit perspective:
  • In women without pregnancy need (post-tubal ligation or with IUD), I avoid combined oral contraceptives for PMS or heavy menses when safer options—cyclic progesterone, IUDs, NSAIDs, and tranexamic acid—can manage symptoms without elevating DVT risk (Lidegaard et al., 2012; Marjoribanks et al., 2016).

Integrative Chiropractic Care: Autonomic Modulation and Tissue-Level Hormone Signaling

How does integrative chiropractic care fit into endocrine therapy? Through autonomic regulation, perfusion, and pain modulation, it improves the terrain in which hormones act.

• Autonomic tone and microcirculation:
  • Chronic pain elevates sympathetic output, constricting peripheral vessels and impairing capillary exchange—precisely where transdermal and pellet hormones are absorbed.
  • Evidence suggests that manual therapy can lower sympathetic arousal, improve HRV, and normalize baroreflex sensitivity, indirectly enhancing tissue perfusion (Pickar & Bolton, 2012).
• Musculoskeletal integration:
  • Pelvic and lumbar dysfunction amplify pelvic floor tension and myofascial pain, worsening menstrual symptoms. Targeted adjustments, soft-tissue mobilization, and neuromuscular reeducation decrease nociceptive input and reduce prostaglandin-driven cramping.
  • Better biomechanics increase exercise adherence, improving insulin sensitivity and lowering androgen excess in PCOS.
• Inflammation and recovery:
  • Low-grade inflammation impairs hormone receptor signaling. Chiropractic interventions, coupled with anti-inflammatory nutrition and sleep hygiene, lower systemic inflammatory markers, thereby improving subjective and objective responses to hormone therapy (Teodorczyk-Injeyan et al., 2018).
• My practice observations:
  • As documented on my platforms, I routinely combine endocrine regimens with spine-pelvis care and rehabilitation pathways so patients tolerate activity, stabilize cycles, and maintain iron repletion more easily.

Practical Dosing Logic for Testosterone Therapy

In individuals, dosing logic should track the pharmacokinetic triad and clinical goals.

• Starting scenarios:
  • Men with low baseline T may experience transient breast tenderness during the first high rise. I preempt this by careful titration, advising on timing and avoiding unnecessary aromatase blockade. If tenderness occurs, I reassess the dose rather than default to inhibitors.
  • Older adults with slower clearance need lower loads and longer intervals.
• Weight changes:
  • After significant weight loss, changes in distribution reduce the required dose. This is why a patient moving from 250 to 190 lb often reaches target levels with less—not more—testosterone.
• Monitoring:
  • Track symptoms, free and total testosterone, estradiol, hematocrit, PSA (men), lipids, liver enzymes, and renal function.
  • Avoid hemoglobin overshoot by adhering to conservative titration and addressing sleep apnea, hydration, and altitude exposure (Coviello et al., 2008).
• Why this approach:
  • Optimizing the dose based on physiology avoids roller-coaster symptoms and reduces unnecessary polypharmacy. It respects estradiol’s protective roles while delivering androgenic benefits for lean mass, libido, mood, and bone health.

Clarifying Myths: ED, Testosterone, and Arrhythmia

Patients and gym peers sometimes conflate erectile dysfunction (ED), testosterone therapy, and cardiac arrhythmias.

• ED is often vascular or neurogenic rather than purely hormonal. Normalizing testosterone may improve libido and erectile quality in hypogonadal men, but ED commonly reflects endothelial health, PDE5 responsiveness, and autonomic balance (Corona et al., 2014).
• Regarding arrhythmia or cardioversion outcomes, some observational data suggest better outcomes in eugonadal men, but arrhythmia pathways are distinct from androgen status. Correct deficiencies and monitor, but do not mechanistically conflate ED and arrhythmia risk.

Premenopausal Versus Menopausal Progestogens: Why the Choice Changes

Why do we use progestins (synthetic progestogens) in premenopausal contraception, yet favor micronized progesterone in perimenopause/menopause?

• Different clinical aims:
  • Contraceptive progestins aim to suppress ovulation and thicken cervical mucus. Their pharmacology prioritizes reliable pregnancy prevention.
  • Menopausal therapy aims to treat symptoms (vasomotor instability, sleep disturbance, mood) and protect the endometrium when using estradiol.
• Physiology and safety:
  • Micronized progesterone shows favorable effects on sleep, mood, and lipids, and may have a more favorable breast and cardiovascular risk profile than several synthetic progestins when combined with transdermal estradiol (Stute et al., 2016).
  • Thus, I choose the molecule based on intent: contraception versus symptom therapy and tissue protection.

Risk of DVT, Stroke, and Contraceptive Strategy in Midlife

Risk stratification matters. In women 40–50 without a need for pregnancy prevention (due to IUD or tubal ligation), the risk-benefit ratio often favors avoiding combined oral contraceptives for symptom control.

• Evidence:
  • Combined oral contraceptives modestly increase venous thromboembolism (VTE) risk, especially with certain progestins and higher estrogen doses (Lidegaard et al., 2012).
  • For heavy menses, consider levonorgestrel IUD, cyclic progesterone, tranexamic acid, and lifestyle-metabolic support—effective without the same VTE profile.
• Clinical pearl:
  • Ask: Is she taking pills for birth control or symptom management? If contraception is unnecessary, switch to lower-risk modalities and treat the underlying physiology.

Environmental Exposures, SHBG, and “Lowering Supplements”

Patients often ask about environmental exposures or supplements marketed to “lower SHBG.”

• Reality check:
  • Many supplements change SHBG by 10–15%, which rarely translates into meaningful symptom change if overall physiology is not addressed (diet, insulin sensitivity, sleep, inflammation).
  • Focus on metabolic health, protein adequacy, resistance training, and thyroid optimization—these have larger effects on androgen bioavailability and symptom relief.

Clinical Workflow: Bringing It All Together

Here is the stepwise approach I use in practice:

• Intake and Testing
  • Comprehensive history, goals, contraception needs, bleeding profile, sleep, exercise, and psychosocial stress
  • Labs: CBC, ferritin, iron panel, TSH, free T4/T3, estradiol/progesterone (cycle-timed if premenopausal), total/free testosterone, SHBG, lipids, CRP, A1C, vitamin D, B12, folate, and renal panel
• Immediate Stabilization
  • Cyclic progesterone if heavy bleeding
  • Iron repletion and thyroid normalization if deficient
  • Pelvic-lumbar chiropractic assessment and targeted manual therapy to reduce pain and autonomic arousal
• Individualized Hormone Strategy
  • PCOS: insulin sensitivity first, progesterone protection, and careful androgen considerations
  • Midlife women with high SHBG: reconsider estrogen-containing contraception; use IUDs or micronized progesterone strategies
  • Men: titrate testosterone with perfusion and clearance in mind; avoid reflex aromatase blockade
• Lifestyle and Integrative Reinforcements
  • Structured exercise progression supported by musculoskeletal care
  • Sleep interventions to normalize cortisol rhythm
  • Anti-inflammatory nutrition and gut support, particularly post-bariatric
• Monitoring and Iteration
  • Symptom scales, lab follow-up, dose adjustments
  • Reinforce rehabilitation and autonomic balance to sustain gains

What Success Looks Like

• Bleeding normalizes, and ferritin rises to ?50–70 ng/mL
• Energy, sleep, mood, and exercise capacity improve
• PCOS patients regain cycle regularity, and metabolic markers improve
• Testosterone recipients achieve stable symptom relief without excessive estradiol blockade or hematocrit elevation
• Patients report reduced pain, better stress tolerance, and consistency in health behaviors—often aided by integrative chiropractic care

Closing Thoughts

Precision hormone care lives at the intersection of endocrinology, metabolism, and neuro-musculoskeletal integration. When we stabilize iron and thyroid, leverage progesterone intelligently, respect SHBG dynamics, and dose androgens according to physiologic kinetics, patients thrive. Integrative chiropractic care strengthens the autonomic and biomechanical foundations that enable these therapies to work more effectively. My commitment is to pursue excellence in every detail—from testing and dosing to recovery and resilience—so each patient experiences consistent, durable improvements.

---

References

• Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S., Legro, R. S., & Lizneva, D. (2016). Polycystic ovary syndrome. https://doi.org/10.1038/nrdp.2016.4
• Cappellini, M. D., Musallam, K. M., Taher, A. T. (2020). Iron deficiency anemia revisited. https://doi.org/10.1038/s41430-020-00740-7
• Corona, G., Rastrelli, G., Maggi, M. (2014). Testosterone replacement therapy: What we know and what we don’t. https://doi.org/10.1111/andr.12056
• Coviello, A. D., Kaplan, B., Lakshman, K. M., Chen, T., & Bhasin, S. (2008). Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. https://doi.org/10.1210/jc.2007-1692
• Finkelstein, J. S., Lee, H., Burnett-Bowie, S.-A. M., Pallais, J. C., Yu, E. W., Borges, L. F., … Bhasin, S. (2013). Estrogen vs testosterone in male sexual function. https://doi.org/10.1056/NEJMoa1206179
• Goddard, A. F., James, M. W., McIntyre, A. S., & Scott, B. B. (2011). Guidelines for the management of iron deficiency anaemia. https://doi.org/10.1136/gut.2010.228874
• Krassas, G. E., Poppe, K., & Glinoer, D. (2010). Thyroid function and human reproductive health. https://doi.org/10.1080/09513590903114118
• Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013). Diagnosis and treatment of PCOS. https://doi.org/10.1210/jc.2013-2350
• Lidegaard, Ø., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E., & Løkkegaard, E. (2012). Risk of venous thromboembolism from contraceptives. https://doi.org/10.1136/bmj.e4544
• Maybin, J. A., & Critchley, H. O. D. (2015). Menstrual physiology and heavy menstrual bleeding. https://doi.org/10.1038/nrgastro.2015.164
• Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Morton, J. M., … Huria, T. (2020). Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures. https://doi.org/10.1007/s11695-020-04432-3
• Pickar, J. G., & Bolton, P. S. (2012). Spinal manipulation and somatosensory control of sympathetic activity. https://doi.org/10.1177/1756283X12452335
• Saad, F., Aversa, A., Isidori, A. M., & Gooren, L. (2017). Testosterone therapy and body composition. https://doi.org/10.1016/j.jsxm.2017.01.002
• Sánchez-Tapia, M., Tovar, A. R., & Torres, N. (2020). Bariatric surgery and gut microbiota. https://doi.org/10.1038/s41574-020-0346-1
• Stute, P., Wildt, L., & Neubert, R. (2016). The impact of micronized progesterone on the endometrium and breast. https://doi.org/10.1016/j.maturitas.2016.03.012
• Zimmerman, Y., Eijkemans, M. J. C., Coelingh Bennink, H. J. T., Blankenstein, M. A., & Fauser, B. C. J. M. (2014). The effect of combined oral contraceptives on SHBG. https://doi.org/10.1210/jc.2013-2396